HiTech Pharmacal Co. Inc.  (HITK) Trade Now »     Rate HITK  -  Discuss HITK  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

HITK Analysis & Videos »


HITK: Bull or Bear?

Big Pharma Goes Generic HITK

73%

+75.94% in 130 days Big Pharma Goes Generic <> <> <> <> <> <> Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  02/26/09

Comment

Hi-Tech Pharmacal: Hi-Growth at a Value Price HITK

73%

+13.19% in 29 days (closed on 02/26/09) Hi-Tech Pharmacal: Hi-Growth at a Value Price   With shares of Home Diagnostics (HDIX) surging by nearly 50% since I profiled the company in mid-December as a turnaround, value play from the ETF Innovators Healthcare Cost Containment Index ; a search for compelling values among these companies today led me to generic drug maker Hi-Tech Pharmacal (HITK).   <> Shares of HITK are down by about 10% in the past five days on light volume and no news headlines, providing a nice chance to accumulate some shares. The Company reported record quarterly revenue for i... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  01/28/09

Comment

Healthcare Hot Spots Beyond Stem Cells HITK

73%

+0.21% in 2 days (closed on 01/28/09) Beyond Stem Cells: Healthcare Hot Spots   With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM).   http://www.etfinnovators.com/2009/01/beyond-stem-cells-health...   <> Below are three additional areas and associated companies for investors to consider in the search of the next hot s... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  01/26/09

Comment

Tender Offer for Taro Pharma Tarries Along HITK

73%

-25.50% in 46 days (closed on 01/26/09) Tender Offer for Taro Pharma Tarries Along <> India's largest generic drug company [ web link to analysis of this market ] by market cap, Sun Pharma (Bombay: 524715), and Israel-based Taro Pharma (TAROF) have one month to reach agreement on an outstanding tender offer of $7.75 per share by Sun Pharma to acquire its smaller rival or the Israel Supreme Court will decide on the case. In early 2007, Taro agreed to the deal as it was struggling to survive and Sun invested $60M as part of a private placement to resolve Taro's liquidity issues. However, in May ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/10/08

Comment

Look for Laggards after Latest Rally HITK

73%

-7.02% in 1 day (closed on 12/10/08) Look For Laggards After Latest Market Rally <> With the S&P 500 SPDR (SPY) trading to the upside by more than 10% in the last five days on the prospects for a short-term $15B rescue package for U.S. auto makers to prevent rising unemployment rates from skyrocketing into double digits, Caraco Pharma (CPD) and Altria Group (MO) represent two laggards from defensive industry groups. The accompanying one-month chart [click to enlarge] illustrates a highly correlated sell-off in Caraco and another small generic drug company, Hi-Tech Pharmacal (HITK), with H... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/09/08

Comment

Generic Cardio Drugs Equal Brands - JAMA HITK

73%

+77.23% in 7 days (closed on 12/09/08) Generic Cardio Drugs Equal Brands - JAMA <> A meta-analysis review of clinical studies published in peer-reviewed journals was featured today in The Journal of the American Medical Association [JAMA] and concluded that cost-saving generics used to treat a variety of cardiovascular conditions produced equivalent clinical outcomes to higher cost brand name drugs. Despite this clinical evidence, the review notes that a majority (53%) of the 43 editorials analyzed had a negative opinion on generic substitution. While there are currently no ETFs on the market w... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/02/08

Comment

A New Index of Healthcare Cost Containment Companies HITK

73%

-28.60% in 12 days (closed on 12/02/08) A New Index of Healthcare Cost Containment Companies <> <> The ETF Innovators [ETFI] Global Healthcare Cost Containment Index profiled in the accompanying table includes companies with market caps over $250M which are involved in the following two segments of the healthcare sector with the common theme of reducing healthcare costs and insurance premiums for consumers, employers, and third-party payers such as the government (through Medicare recipients) and insurance companies. Generic Healthcare Products: This category includes generic prescription a... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/20/08

Comment

10 Under the Radar Small & Micro-Cap Value Stocks HITK

73%

-3.43% in 5 days (closed on 11/20/08) 10 Under the Radar Small & Micro-Cap Value Stocks (Healthcare) <> The accompanying table presents 10 small and micro-cap companies from a variety of industries which are trading at value parameters, with average valuations for the group of 0.54X trailing 12-month sales, 0.44X enterprise value to sales, 0.88X book value, and 8.7X trailing 12-month earnings. The iShares Russell 2000 Small-Cap Value ETF (IWN) has lost about 39% in the past year and serves as a useful ETF benchmark comparison for these companies. Healthcare – Diagnostics: Home Diagnostics (HDI< />< /><>< />< /><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/15/08

Comment

A Bullish Outlook for Generic Drugs After Election HITK

73%

-20.86% in 11 days (closed on 11/15/08) A Bullish Outlook for Generic Drugs After Election <> In addition to the favorable underlying trends I wrote about previously for the generic drug industry, both presidential candidates are bullish on the industry with the following excerpts taken directly from their websites: Senator Obama : Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs and taking on drug companies that block cheaper generic medicines from the market. Senator McCain : R... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/04/08

Comment

People Bullish on HITK

Mike Havrilla Principal 73% 4 mos ago

People Bearish on HITK

crispy Sr. Associate 74% over 2 years ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.